THRESHOLD PHARMACEUTICALS INC Form SC 13G/A December 10, 2014

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G/A

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(AMENDMENT 2)

Threshold Pharmaceuticals, Inc.

(NAME OF ISSUER)

COMMON STOCK

(Title of Class of Securities)

885807206

(CUSIP Number)

NOVEMBER 28, 2014

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

X Rule 13d-1 (b)

Rule 13d-1 (c)

Rule 13d-1 (d)

CUSIP No. 885807206		13G/A	Page 1 of 3 pages
1. Names of reporting	persons	JPMorgan Chase & Co.	
I.R.S. IDENTIFICA (ENTITIES ONLY		0. OF ABOVE PERSONS	13-2624428
2. CHECK THE APP GROUP*	PROPRIAT	E BOX IF A MEMBER OF A	(a)
			(b)
3. SEC USE ON	ILY		
4. CITIZENSHI Delaware	P OR PLA	CE OF ORGANIZATION	
NUMBER OF	5.	SOLE VOTING POWER	657,165
SHARES			
BENEFICIALLY	6.	SHARED VOTING POWER	0
OWNED BY			
EACH	7.	SOLE DISPOSITIVE POWER	834,065
REPORTING			

Edgar Filing: THRESHOLD PHARMACEUTICALS INC - Form SC 13G/A

PERSON WITH 8. SHARED DISPOSITIVE 0 POWER

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

857,565

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.3%

12. TYPE OF REPORTING PERSON*

HC

Item 1(a).	Name of Issuer:
	Threshold Pharmaceuticals, Inc.
Item 1(b).	Address of Issuer's Principal Executive Offices:
	170 Harbor Way, Suite 300
	South San Francisco, CA 94080
Item 2(a).	Name of Person Filing:
	JPMorgan Chase & Co.

Edgar Filing: THRESHOLD PHARMACEUTICALS INC - Form SC 13G/A Address of Principal Business Office or, if None, Residence: Item 2(b). 270 PARK AVE NEW YORK, NY 10017 Citizenship Item 2(c). Delaware Title of Class of Securities: Item 2(d). COMMON STOCK Unless otherwise noted, security being reported is common stock **CUSIP** Number: 885807206 Item 2(e). If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) Item 3 Or (c), Check Whether the Person Filing is a : Broker or dealer registered under Section 15 of the Exchange (a) Act; (b) Bank as defined in Section 3(a)(6) of the Exchange Act; (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act; (d) Investment company registered under Section 8 of the Investment Company Act; An investment adviser in accordance with Rule (e)

(f)

13d-1(b)(1)(ii)(E);

4

An employee benefit plan or endowment fund in accordance with

Rule 13d-1(b)(1)(ii)(F);

- (g) X A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) A church plan that is excluded from the definition of an Investment company under Section 3(c)(14) of the Investment Company act;
- (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
- If this statement is filed pursuant to X Rule 13d-1(b), check this box.

```
Page 2 of 3 pages
```

Item 4. Ownership

Provide the following information regarding the aggregate number and

Percentage of the class of securities of issuer identified in Item 1.

(a) Amount beneficially owned:

857,565

Including

0 shares where there is a Right to Acquire.

(b) Percent of class:

1.3%

Edgar Filing: THRESHOLD PHARMACEUTICALS INC - Form SC 13G/A

(c) Number of shares as to which such person has:

(i)	Sole power to vote or to direct the vote:	657,165
(ii)	Shared power to vote or to direct the vote:	0
(iii)	Sole power to dispose or to direct the disposition of:	834,065
(iv)	Shared power to dispose or to direct the disposition of:	0

Item 5. Ownership of Five Percent or Less of a Class. YES

If this statement is being filed to report the fact that as of the date

hereof the reporting person has ceased to be the beneficial owner of more

than five percent of the class of securities, check the following.

(X)

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

JPMorgan Chase & Co. is the beneficial owner of

857,565 shares of the

issuer's common stock on behalf of other persons known to have one or more of

the following:

the right to receive dividends for such securities; the power to direct the receipt of dividends from such securities; the right to receive the proceeds from the sale of such securities; the right to direct the receipt of proceeds from the sale of such securities;

Edgar Filing: THRESHOLD PHARMACEUTICALS INC - Form SC 13G/A

No such person is known to have an interest in more than 5% of the class of securities reported herein unless such person is identified below.

Item 7. Identification and Classification of the Subsidiary Which Acquired the

Security being reported on by the Parent Holding Company.

This notice is filed on behalf of JPMorgan Chase & Co. and its wholly owned

Subsidiary (ies),

JPMorgan Chase Bank, National Association

- J.P. Morgan Investment Management Inc.
- **Item 8.** Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group. Not Applicable

Item Certifications 10.

By signing below I certify that, to the best of my knowledge and belief,

the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 3 of 3 pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the

information set forth in this statement is true, complete and correct.

Dated: DECEMBER 10, 2014

JPMorgan Chase & Co.

By: /s/ Margaret R. Rubin

Margaret R. Rubin

Compliance

The original statement shall be signed by each person on whose behalf the statement

is filed or his authorized representative. If the statement is signed on behalf of

a person by his authorized representative (other than an executive officer or general

partner of the filing person), evidence of the representative's authority to sign on

behalf of such person shall be filed with the statement, provided, however, that a

power of attorney for this purpose which is already on file with the commission may

be incorporated by reference. The name and any title of each person who signs the

the statement shall be typed or printed beneath his signature.